- Home
- ESRT vs LGND Comparison
ESRT vs LGND Comparison
Compare ESRT & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESRT
- LGND
- Stock Information
- Founded
- ESRT 2011
- LGND 1987
- Country
- ESRT United States
- LGND United States
- Employees
- ESRT N/A
- LGND N/A
- Industry
- ESRT Real Estate Investment Trusts
- LGND Biotechnology: Pharmaceutical Preparations
- Sector
- ESRT Real Estate
- LGND Health Care
- Exchange
- ESRT Nasdaq
- LGND Nasdaq
- Market Cap
- ESRT 1.8B
- LGND 2.0B
- IPO Year
- ESRT 2013
- LGND 1992
- Fundamental
- Price
- ESRT $10.60
- LGND $111.71
- Analyst Decision
- ESRT Hold
- LGND Strong Buy
- Analyst Count
- ESRT 3
- LGND 6
- Target Price
- ESRT $10.67
- LGND $144.83
- AVG Volume (30 Days)
- ESRT 1.2M
- LGND 142.9K
- Earning Date
- ESRT 10-21-2024
- LGND 11-07-2024
- Dividend Yield
- ESRT 1.32%
- LGND N/A
- EPS Growth
- ESRT N/A
- LGND 160.46
- EPS
- ESRT 0.27
- LGND 2.47
- Revenue
- ESRT $763,203,000.00
- LGND $152,422,000.00
- Revenue This Year
- ESRT N/A
- LGND $23.19
- Revenue Next Year
- ESRT $2.20
- LGND $15.08
- P/E Ratio
- ESRT $38.80
- LGND $45.20
- Revenue Growth
- ESRT 4.84
- LGND N/A
- 52 Week Low
- ESRT $8.39
- LGND $57.00
- 52 Week High
- ESRT $11.62
- LGND $129.90
- Technical
- Relative Strength Index (RSI)
- ESRT 41.98
- LGND 48.80
- Support Level
- ESRT $10.76
- LGND $119.69
- Resistance Level
- ESRT $11.01
- LGND $125.76
- Average True Range (ATR)
- ESRT 0.24
- LGND 5.73
- MACD
- ESRT -0.03
- LGND -0.30
- Stochastic Oscillator
- ESRT 19.14
- LGND 25.51
About ESRT Empire State Realty Trust Inc.
Empire State Realty Trust operates as a pure-play greater New York and Manhattan-focused REIT, featuring its landmark Empire State Building office and observation deck. The company owns and operates around 8.5 million square feet of office space, about 80% of which is located in Manhattan.
About LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.